Study summary

The purpose of this study is to evaluate the efficacy of ASP8232 in reducing Urinary Albumin to Creatinine Ratio (UACR) in subjects with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) at 12 weeks compared to placebo.

Additional Study Details

Phase
2
Product
  • ASP8232
  • Placebo
  • Type
    Interventional
    Masking
    Triple (Participant, Investigator, Outcomes Assessor)
    Enrollment number
    125
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Plain Language Summary
    Available Language(s): English

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients with Type 2 Diabetes and Chronic Kidney Disease? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • Former Serbia and Montenegro
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Republic of Korea
    • Republic of Moldova
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Completed
      Site ES34004
      Barcelona, Barcelona, Spain, 08035
      Completed
      Site PL48006
      Rzeszow, Poland, 35-055
      Completed
      Site DK45006
      Viborg, Denmark, 8800
      Completed
      Site GB44005
      London, United Kingdom, SE1 9RT
      Completed
      Site ES34005
      Barcelona, Spain, 08025
      Completed
      Site IT39005
      Pavia, Italy, 27100
      Completed
      Site ES34001
      Barcelona, Barcelona, Spain, 08003
      Completed
      Site CZ42002
      Brno, Czech Republic
      Completed
      Site ES34006
      Lugo, Spain, 27880
      Completed
      Site DE49002
      Düsseldorf, Germany, 40210
      Completed
      Site PL48004
      Lodz, Poland, 94-225
      Completed
      Site CZ42003
      Ceské Budejovice, Czech Republic, 370 01
      Completed
      Site PL48003
      Plock, Poland, 09-402
      Completed
      Site HU36017
      Szekesfehervar, Hungary, 8000
      Completed
      Site DK45004
      Gentofte, Denmark, 2820
      Completed
      Site PL48008
      Lodz, Poland, 94-048
      Completed
      Site IT39012
      Rome, Italy, 00189
      Completed
      Site IT39004
      Turin, Italy, 10141
      Withdrawn
      Site BE32004
      Roeselare, Belgium, 8800
      Completed
      Site CZ42005
      Praha 10, Czech Republic, 108 00
      Completed
      Site HU36003
      Hatvan, Hungary, H-3000
      Completed
      Site HU36010
      Budapest, Hungary, H-1096
      Completed
      Site ES34002
      Barcelona, Barcelona, Spain, 08907
      Completed
      Site HU36018
      Veszprem, Hungary, H- 8200
      Completed
      Site HU36012
      Kaposvar, Hungary, 7400
      Completed
      Site GB44004
      Burton-on-Trent, United Kingdom, DE13 0RB
      Completed
      Site CZ42001
      Prague 4, Czech Republic, 140 21
      Completed
      Site GB44001
      Chester, United Kingdom, CH2 1UL
      Withdrawn
      Site NL31002
      Eindhoven, Netherlands, 5631 BM
      Completed
      Site DK45001
      Herlev, Denmark, 2730
      Completed
      Site IT39007
      Bergamo, Italy, 24127
      Withdrawn
      Site DK45003
      Frederiksberg, Denmark, 2000
      Completed
      Site DE49008
      Elsterwerda, Germany, 04910
      Completed
      Site HU36016
      Budapest, Hungary, 1036
      Completed
      Site ES34003
      PALMA DE MALLORCA, Spain, 7120
      Completed
      Site GB44003
      South Yorkshire, United Kingdom, DN2 5LT
      Completed
      Site PL48005
      Sopot, Poland
      Withdrawn
      Site BE32002
      Brussels, Belgium, 1070
      Withdrawn
      Site DE49007
      Bosenheim, Germany, 55545
      Withdrawn
      Site PL48028
      Kraków, Poland, 30-069
      Completed
      Site PL48027
      Oświęcim, Poland, 32-600
      Completed
      Site HU36005
      Szikszó, Hungary
      Completed
      Site DE49003
      Heidelberg, Germany, 69115
      Completed
      Site DE49004
      Berlin, Germany, 13125
      Completed
      Site DK45002
      Hillerød, Denmark, 3400
      Completed
      Site DK45016
      Copenhagen, Denmark, 2400
      Completed
      Site NL31001
      Dordrecht, Netherlands, 3318 AT
      Completed
      Site PL48022
      Radom, Poland, 26-600
      Completed
      Site IT39002
      Piacenza, Italy, 29100
      Completed
      Site PL48001
      Poznan, Poland, 61655
      Completed
      Site DK45007
      Holsterbro, Denmark, 7500
      Completed
      Site HU36002
      Balatonfüred, Hungary, 8230
      Completed
      Site CZ42004
      Praha 9, Czech Republic, 190 00
      Completed
      Site ES34012
      Madrid, Spain, 28041
      Withdrawn
      Site DE49006
      Berlin, Germany, 13353
      Completed
      Site ES34010
      Majadahonda, Spain, 28222
      Completed
      Site ES34007
      Ciudad Real, Spain, 13005
      Completed
      Site PL48026
      Lodz, Poland, 90-302
      Completed
      Site NL31004
      Rotterdam, Zuid-Holland, Netherlands, 3045 PM
      Completed
      Site ES34008
      Madrid, Spain, 28007
      Completed
      Site PL48025
      Warszawa, Poland, 00-660
      Completed
      Site NL31003
      Hoogeveen, Netherlands, 7909 AA
      Withdrawn
      Site BE32001
      Brussels, Belgium, 1090
      Completed
      Site HU36007
      Szigetvar, Hungary, 7900
      Completed
      Site PL48002
      Torun, Poland, 87-100

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      2

      Why are Clinical Trials Important?

      3

      Why Participate in a Clinical Trial?